Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
Cell · 2024-09 · 187 (18) · 4890-4904.e9
DOI: 10.1016/j.cell.2024.06.027 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Cell, 2024-09. Verfasst von Xiaobing Wang und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China; National Key Laboratory fo…. Hauptthemen laut MEDLINE: Antigens, CD19, Immunotherapy, Adoptive, Myositis, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 331-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, National Key Research and Development Program of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China; National Key Laboratory for Immunity and Inflammation, Shanghai, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology and School of Life Sciences, East China Normal University, Shanghai 200241, China; BRL Medicine Inc., S…
- Department of Rheumatology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
- Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- Department of Radiology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- National Key Laboratory for Immunity and Inflammation, Shanghai, China; Department of Pathology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200082, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- National Key Research and Development Program of China
Zitieren
APA
Wang, X., Wu, X., Tan, B., Zhu, L., Zhang, Y., Lin, L., Xiao, Y., Sun, A., Wan, X., Liu, S., Liu, Y., Ta, N., Zhang, H., Song, J., Li, T., Zhou, L., Yin, J., Ye, L., Lu, H., …, & Xu, H. (2024). Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell, 187(18), 4890-4904.e9. https://doi.org/10.1016/j.cell.2024.06.027
Vancouver
Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890-4904.e9. doi:10.1016/j.cell.2024.06.027
BibTeX
@article{Wang2024,
author = {Wang, Xiaobing and Wu, Xin and Tan, Binghe and Zhu, Liang and Zhang, Yi and Lin, Li and Xiao, Yi and Sun, An and Wan, Xinyi and Liu, Shiyuan and Liu, Yanfang and Ta, Na and Zhang, Hang and Song, Jialin and Li, Ting and Zhou, Ling and Yin, Jian and Ye, Lingying and Lu, Hongjuan and Hong, Jinwei and Cheng, Hui and Wang, Ping and Li, Weiqing and Chen, Jianfeng and Zhang, Jin and Luo, Jing and Huang, Miaozhen and Guo, Lehang and Pan, Xiaoming and Jin, Yi and Ye, Wenjing and Dai, Lie and Zhu, Jian and Sun, Lingyun and Zheng, Biao and Li, Dali and He, Yanran and Liu, Mingyao and Wu, Huaxiang and Du, Bing and Xu, Huji},
title = {Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis},
journal = {Cell},
year = {2024},
volume = {187},
number = {18},
pages = {4890--4904.e9},
doi = {10.1016/j.cell.2024.06.027}
}
EUVIMED